A Phase 1 interventional study of CVL-231 and Matching Placebo in Schizophrenia, sponsored by Cerevel Therapeutics, LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-07-02.
Sponsored by Cerevel Therapeutics, LLC (part of AbbVie) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.
Among the 27 studies in Schizophrenia by AbbVie, this one is the 20th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 1, and was the 18th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 268 across the 27 interventional studies. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Cerevel Therapeutics, LLC, one of the names counted as AbbVie. Under that name alone:
Cerevel Therapeutics, LLC is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 1 (5%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Schizophrenia by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-231 following multiple-dose oral administration in subjects with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohorts 1 Through 5 (Part A):
Subjects are eligible to be included in trial (Cohorts 1 through 5) only if all of the following additional criteria apply:
Cohort 6 (Part B):
Subjects are eligible to be included in trial (Cohort 6) only if all of the following additional criteria apply:
Subjects with a PANSS total score of ≥80 at the time of signing ICF and at Day -1. Additionally, subjects must meet a score of ≥4 (moderate or greater) for ≥2 of the following Positive Scale items at the time of signing ICF and at Day -1:
Exclusion Criteria:
Cohorts 1 Through 5 (Part A) Subjects are excluded from the trial (Cohorts 1 through 5) if any of the following additional criteria apply:
Subjects with a 12-lead ECG demonstrating any of the following:
Cohort 6 (Part B) Only Subjects are excluded from trial (Cohort 6 only) if any of the following additional criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Dose
Drug: CVL-231
Matching Placebo; Oral Dose
Drug: Matching Placebo
Oral Dose
Drug: CVL-231
Matching Placebo; Oral Dose
Drug: Matching Placebo
Oral Dose
Drug: CVL-231
Matching Placebo; Oral Dose
Drug: Matching Placebo
Oral Dose
Drug: CVL-231
Matching Placebo; Oral Dose
Drug: Matching Placebo
Oral Dose
Drug: CVL-231
Matching Placebo; Oral Dose
Drug: Matching Placebo
Oral Dose
Drug: CVL-231
Matching Placebo; Oral Dose
Drug: Matching Placebo
Oral Dose
Drug: CVL-231
Drug: Matching Placebo
CVL-231
Placebo matching CVL-231
Incidence of Treatment Emergent Adverse Events (TEAEs)
Includes Incidence of Significant ECG Abnormalities Occurring Post-Baseline, significant changes in Vital signs (Systolic and Diastolic blood pressures, heart rate, respiratory rate and body temperature), and changes in laboratory measures (hematology, serum chemistry and urinalysis)
Time frame: Up to Day 72
Incidence of suicidality as assessed by Columbia-Suicide Severity Rating Scale(C-SSRS)
The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).
Time frame: Up to Day 72
Change from Baseline of Simpson-Angus Scale (SAS) Results
Evaluating Extrapyramidal symptoms using the SAS. The SAS consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items.
Time frame: Up to Day 72
Change from Baseline of Abnormal Involuntary Movement Scale (AIMS) Results
The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the subject is at rest, and the investigator also makes global judgments on the subject's dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the subject's dental status. The AIMS Movement Rating Score is defined as the sum of items 1 through 7 (ie, items 1 through 4, facial and oral movements; items 5 and 6, extremity movements; and item 7, trunk movements).
Time frame: Up to Day 72
Change from Baseline of Barnes Akathisia Rating Scale (BARS) Results
Evaluating Extrapyramidal symptoms using the BARS. The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the subject, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia.
Time frame: Up to Day 72
Single-dose: Area under the plasma concentration vs. time curve (AUC) for CVL-231 and Metabolite (PF-06892787)
Time frame: Day 1
Single-dose: Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (PF-06892787)
Time frame: Day 1
Single-dose: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (PF-06892787)
Time frame: Day 1
Single-dose: Metabolite to parent ratio for Cmax for CVL-231 and Metabolite (PF-06892787)
Time frame: Day 1
Single-dose: Metabolite to parent ratio for AUC tau for CVL-231 and Metabolite (PF-06892787)
Time frame: Day 1
Multiple-dose: Steady state CVL-231 Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Trough plasma concentration (Ctrough) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Minimum blood plasma concentration (Cmin) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Area under the plasma concentration-time curve (AUCτ) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Apparent Total Clearance of Drug from plasma: CL/F for CVL-231
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Steady-state average plasma drug concentration: Css for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Peak Trough Ratio (PTR) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Accumulation ratio calculated from Cmax,ss and Cmax after single dosing (Rac, Cmax) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Accumulation ratio calculated from AUCτ,ss and AUCτ after single dosing (Rac, AUC) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28 and/or 36
Multiple-dose: Elimination half-life (t½) for CVL-231 and Metabolite (PF-06892787)
Time frame: Day 14-17 and/or Day 28-31
Multiple-dose: Elimination rate constant (kel) for CVL-231 and Metabolite (PF-06892787)
Time frame: Day 14-17 and/or Day 28-31
Multiple-dose: Ae (amount eliminated unchanged in urine) for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28
Multiple-dose: Renal clearance for parent only for CVL-231
Time frame: Days 14 and/or 28
Multiple-dose: Metabolite to parent ratio for Cmax for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28
Multiple-dose: Metabolite to parent ratio for AUCtau for CVL-231 and Metabolite (PF-06892787)
Time frame: Days 14 and/or 28
Ran from Oct 2019 to primary completion in May 2021, 18 months.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 18 months is above that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emraclidine